eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2021
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

Chemokine receptor CXCR6 gene polymorphism and treatment response of chronic hepatitis C virus in Egyptian patients

Mona M Hassona
1
,
Tamer Fouad
2
,
Merhan Osama Helmi
1
,
Heba Samy Mohammed Ghanem
1
,
Heba E Abd Elrhman
3
,
Eman Abdelsameea
4

  1. Clinical Pathology, National Liver Institute, Menoufia University, Egypt
  2. Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt
  3. Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt
  4. National Liver Institute, Egypt
Clin Exp HEPATOL 2021; 7, 4: 370-376
DOI: https://doi.org/10.5114/ceh.2021.111490
Online publish date: 2021/12/23
View full text Get citation
 
PlumX metrics:
Introduction
Despite achieving a high cure rate of chronic hepatitis C nowadays, treatment failure remains a major concern and host genetic polymorphism could have a possible relation. The aim was to evaluate the role of chemokine receptor CXCR6 gene polymorphism in treatment response to direct acting antivirals (DAAs) in chronic hepatitis C virus (HCV) patients.

Material and methods
We investigated the chemokine receptor CXCR6 gene single nucleotide polymorphism rs2234358 in three groups. Responder and non-responder groups (each comprising 50 naïve patients) and a control group of 50 apparently healthy individuals were studied.

Results
Genotype distribution revealed a significant difference (p = 0.037) between non-responders and the other 2 groups. Both control and responder groups showed allelic frequencies of 20% having the wild allele G and 80% having the variant allele T, while in the non-responder group 39% had G and 61% had the T alleles. Genotype GG was associated with significant increased risk of not responding to treatment by 4.25 times as compared with TT genotype (p = 0.019) and the G allele was associated with highly significant risk of not responding to treatment by 2.56 times compared with the T allele (p = 0.003).

Conclusions
CXCR6 gene (rs2234358) polymorphism could have a potential role in the virological treatment response with a protective effect of the T allele. This could explain the higher treatment success rate of Egyptian HCV patients.

keywords:

hepatitis C virus (HCV), direct-acting antivirals (DAAs), CXCR6, polymorphism, sustained virological response
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.